Olaparib (Lynparza) in women who have high-grade epithelial ovarian cancer and are having a platinum-sensitive relapse
In 2018, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into whether olaparib has any advantages or disadvantages compared with the watchful waiting approach in women with high-grade epithelial ovarian cancer who are having a platinum-sensitive relapse.
The manufacturer provided two studies involving 560 women with usable data. Almost all of the women had serous ovarian cancer.
The results of one of the studies (involving a total of 265 women) were analyzed after about 8 years. The other study (involving a total of 295 women) is still on-going, but an interim analysis was completed after about 3 years. Overall, 332 women received olaparib and 228 women were given the standard treatment (watchful waiting). Some initial conclusions can be drawn from these two studies.